SCNX Market Analysis
Wall Street coverage
third-party contextWall Street coverage
Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.
News & Sentiment
50 articles · sorted by dateVia 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.
Fundamentals
Updated daily after market closeValuation
- Forward P/E
- 21.83
- PEG ratio
- —
- P/B
- 0.23
- P/S (TTM)
- 32.38
- EV/EBITDA
- -1.56
Profitability & growth
- ROE (TTM)
- -56.6%
- Operating margin
- -6231.0%
- Revenue growth YoY
- 449.1%
- Dividend yield
- —
- Beta
- 4.08
Ratios are point-in-time. Historical metrics — no guarantees about what comes next.
About Scienture Holdings, Inc.
Company profileScienture Holdings, Inc. (SCNX) is a pioneering biotechnology firm focused on transforming the treatment landscape for neurological disorders through its advanced drug development pipeline and a seasoned research team. The company is dedicated to addressing significant unmet medical needs, highlighting its potential to enhance patient outcomes while skillfully navigating regulatory complexities. With a strong emphasis on scientific integrity and strategic collaborations, Scienture is well-positioned to leverage growth opportunities in the burgeoning global healthcare market, particularly as…
Classification
- Sector
- Healthcare
- Industry
- Pharmaceutical Retailers
- Exchange
- NASDAQ
- Country
- USA
- Currency
- USD
Company profile
- HQ
- 20 AUSTIN BOULEVARD, COMMACK, NY
- Fiscal year end
- December
- Latest quarter
- Mar 31, 2026
We're educators, not advisors. We don't make buy or sell recommendations under any circumstance. All content is for educational purposes. Past performance doesn't guarantee future results. Your decisions are your own. Disclaimer
